Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.09, Briefing.com reports. During the same quarter last year, the business posted ($0.62) EPS. Syndax Pharmaceuticals Stock Down 2.9 % SNDX traded down $0.59 during midday […]
Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.09, Briefing.com reports. During the same period in the previous year, the firm earned ($0.62) earnings per share. Syndax Pharmaceuticals Stock Performance Shares of Syndax Pharmaceuticals […]
Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) had its price target lifted by Barclays from $31.00 to $34.00 in a research report sent to investors on Wednesday, Marketbeat.com reports. They currently have an overweight rating on the stock. SNDX has been the subject of several other reports. StockNews.com raised shares of Syndax Pharmaceuticals to a sell […]
Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) had its target price increased by Guggenheim from $40.00 to $42.00 in a research report issued to clients and investors on Monday, Marketbeat Ratings reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s price objective would indicate a potential upside of 94.17% from the company’s […]
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) has been given an average rating of “Buy” by the eight analysts that are presently covering the company, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have covered the stock in the last […]